Abdel-Ghany Shaimaa, Raslan Sara, Tombuloglu Huseyin, Shamseddin Aly, Cevik Emre, Said Osama A, Madyan Engy F, Senel Mehmet, Bozkurt Ayhan, Rehman Suriya, Sabit Hussein
Department of Environmental Biotechnology, College of Biotechnology, Misr University for Science and Technology, P. O. Box 77, Giza, Egypt.
Department of Genetics, Institute for Medical Research and Consultations, Imam Abdulrahman Bin Faisal University, P. O. Box: 1982, Dammam, 31441 Saudi Arabia.
3 Biotech. 2020 Sep;10(9):407. doi: 10.1007/s13205-020-02391-2. Epub 2020 Aug 27.
Breast cancer is a group of diseases in which cells divide out of controlled, typically resulting in a mass. Erlotinib is targeted cancer drug which functions as an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It is used mainly to treat of non-small cell lung cancer patients and has an action against pancreatic cancer. Vorinostat ( suberanilohydroxamic acid) is an inhibitor of histone deacetylases (HDAC), which has an epigenetic modulation activity. It is used to treat cutaneous T cell lymphoma. In the present study, the erlotinib (ERL) and vorinostat (SAHA) loaded TiO nanoparticles (NPs) were used for the treatment of the breast cancer cells (MDA-MB-231 and MCF-7) and human cancerous amniotic cells (WISH). Cell count and viability were negatively affected in all treatments compared to normal cells and bare TiO NPs. Apoptosis results indicated a significant increase in the total apoptosis in all treatments compared with control cells. ERL- and SAHA-loaded TiO NPs treatments arrested breast cancer cells at G2/M phase, which indicate the cytotoxic effect of these treatment. Partner and localizer of () gene expression was assessed using qPCR. The results indicate that was upregulated in ERL- and SAHA-loaded TiO NPs compared with control cells and can be used as nanocarrier for chemotherapy drugs. However, this conclusion necessitates further confirmative investigation.
乳腺癌是一组细胞失控分裂的疾病，通常会形成肿块。厄洛替尼是一种靶向抗癌药物，作为表皮生长因子受体（EGFR）酪氨酸激酶的抑制剂发挥作用。它主要用于治疗非小细胞肺癌患者，对胰腺癌也有疗效。伏立诺他（辛二酰苯胺异羟肟酸）是组蛋白脱乙酰酶（HDAC）的抑制剂，具有表观遗传调节活性。它用于治疗皮肤T细胞淋巴瘤。在本研究中，负载厄洛替尼（ERL）和伏立诺他（SAHA）的二氧化钛纳米颗粒（NPs）用于治疗乳腺癌细胞（MDA-MB-231和MCF-7）和人癌性羊膜细胞（WISH）。与正常细胞和裸露的二氧化钛纳米颗粒相比，所有处理中的细胞计数和活力均受到负面影响。凋亡结果表明，与对照细胞相比，所有处理中的总凋亡均显著增加。负载ERL和SAHA的二氧化钛纳米颗粒处理使乳腺癌细胞停滞在G2/M期，这表明了这些处理的细胞毒性作用。使用qPCR评估（）基因表达的伙伴和定位器。结果表明，与对照细胞相比，负载ERL和SAHA的二氧化钛纳米颗粒中该基因上调，并且可以用作化疗药物的纳米载体。然而，这一结论需要进一步的验证性研究。
